ACRS250516C7000
- 0.14
- 0.000.00%
Aclaris Therapeutics Newsroom
Scotiabank Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Cuts Target Price to $9
Aclaris Therapeutics Is Maintained at Sector Outperform by Scotiabank
Aclaris Therapeutics Price Target Cut to $9.00/Share From $15.00 by Scotiabank
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series
Aclaris Therapeutics | 10-Q: Quarterly report
Aclaris Therapeutics Reports Q1 EPS (12c), Consensus (12c)
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Express News | Aclaris Therapeutics Q1 Net Income USD -15.085 Million Vs. IBES Estimate USD -13.3 Million
Express News | Aclaris Therapeutics Q1 Revenue USD 1.455 Million Vs. IBES Estimate USD 1.28 Million
Press Release: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics 1Q Loss $15.1M >ACRS
Aclaris Therapeutics 1Q Rev $1.46M >ACRS
Aclaris Therapeutics 1Q Loss/Shr 12c >ACRS
Express News | Aclaris Therapeutics Appoints Jesse Hall, M.d. as Chief Medical Officer
Press Release: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Strong Week for Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Doesn't Alleviate Pain of Three-year Loss
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2
Express News | Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody
Aclaris Therapeutics Assumed With an Overweight at Cantor Fitzgerald